To Compare the Efficacy of (Rifaximin + Mebeverine), (Rifaximin + Amitriptyline), and (Rifaximin + Psyllium Husk) in Irritable Bowel Syndrome Associated With Diarrhea

Bahria University1 个研究点分布在 1 个国家目标入组 162 人开始时间: 2023年1月3日最近更新: 2023年7月27日

适应症

干预措施

试验速览

阶段: 4 期
状态: 已完成
发起方: Bahria University
入组人数: 162
试验地点: 1
主要终点: Compare Efficacy of Treatment Regimes in Treatment Groups

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The goal of this clinical trial is to compare the efficacy of four different drugs in combination for management of irritable bowel syndrome (IBS)-associated diarrhea. The main question to answer is:

Is there a significant difference in effect of different drug combinations in management of irritable bowel syndrome with diarrhea?

Participants will be divided into 3 treatment groups.

Each group will be given a combination of drugs for 2 weeks
At the end of study, efficacy of different drug combinations and their potential side effects will be compared between the treatment groups

详细描述

The goal of this clinical trial is to compare the efficacy of four different drugs (Rifaximin , Mebeverine, Amitriptyline and Psyllium Husk) in combination for management of irritable bowel syndrome (IBS)-associated diarrhea. The main question to answer is:

• Is there a significant difference in effect of different drug combinations in management of irritable bowel syndrome with diarrhea?

Total of 162 Participants will be enrolled in study.

Participants will be divided into 3 treatment groups i.e. Group A, Group B and Group C.
Participants of Group A will receive drug combination of Rifaximin and Mebeverine
Participants of Group B will receive drug combination of Rifaximin and Amitriptyline
Participants of Group C will receive drug combination of Rifaximin and Psyllium Husk
Each group will be given a combination of drugs for 2 weeks

Stool Frequency, Characteristic of Stool and Abdominal Pain will be assessed at day 0 and day 14 of intervention

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 45 Years（Adult）
性别: All
接受健康志愿者: 否

入选标准

•Individual of both gender between the age of 18-50 years Diagnosed case of Irritable Bowel Syndrome associated with Diarrhea

排除标准

•Presence of co morbid diseases
•Coronary Artery Disease (CAD)
•Chronic Obstructive Pulmonary Disease (COPD)
•Congestive Heart Failure (CHF)
•Patients taking drugs which modify or aggravate symptoms of IBS (antidepressants, calcium channel blockers etc.)
•Patients having hyperthyroidism & gluten hypersensitivity
•Patients with alarming symptoms, viz. history of fever, passage of blood in stool, loss of weight, any organic gastrointestinal disease in the recent past
•Patients with recent change in bowel habits, patients on any other concomitant medication for abdominal pain, bowel disturbance or altering gastrointestinal motility and malignancy of any other organ
•Patients with Irritable Bowel Disease and Celiac disease